Surgical Management of Retroperitoneal Liposarcoma: Opportunities for Multimodality Treatment, Including Systemic Therapy
Cancer Medicine · 2025-08 · 14 (15)
DOI: 10.1002/cam4.71129 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 08.08.2025. Verfasst von Steven Sun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, California, USA. Hauptthemen laut MEDLINE: Liposarcoma, Retroperitoneal Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim USA.
Abstract (Originalsprache)
Introduction
Soft tissue sarcomas are a diverse group of rare cancers, with approximately 15%–20% found in the retroperitoneum. Liposarcomas (LPS) make up approximately half of all retroperitoneal (RP) sarcomas, with most cases classified as either well‐differentiated (WD) or dedifferentiated (DD). DD LPS is more aggressive, with a higher local recurrence rate and risk of distant metastasis compared to WD LPS. The purpose of this review is to outline surgical management of RP LPS and highlight the multimodal treatment strategies for both primary and recurrent disease, along with considerations for their effective implementation.
Methods
The current medical literature was reviewed for studies focused on retroperitoneal liposarcoma and its treatment with surgery, radiation, and chemotherapy. The data was interpreted and compiled in the context of expert clinical experience.
Results
Along with histopathologic analysis, tumor biology can inform patient prognosis. Surgery, the standard treatment for RP LPS, can be either curative or palliative. In primary disease, an attempt should be made to achieve wide surgical margins when feasible. Surgery for recurrent disease requires careful timing and an understanding of the potential benefit versus risk. Neoadjuvant radiation therapy can improve local control of RP LPS; however, data supporting the use of neoadjuvant chemotherapy are currently lacking.
Conclusion
Multimodality treatment of RP LPS is complex and requires consideration of tumor biology and extent of disease, along with individual patient characteristics. Multidisciplinary team collaboration is critical for improving outcomes in patients with RP LPS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, California, USA.
- Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.
ORCID-Profile: Steven Sun, Kenneth Cardona, William W Tseng
Förderung
- Boehringer Ingelheim USA
Zitieren
APA
Sun, S., Cardona, K., & Tseng, W. W. (2025). Surgical Management of Retroperitoneal Liposarcoma: Opportunities for Multimodality Treatment, Including Systemic Therapy. Cancer Medicine, 14(15). https://doi.org/10.1002/cam4.71129
Vancouver
Sun S, Cardona K, Tseng WW. Surgical Management of Retroperitoneal Liposarcoma: Opportunities for Multimodality Treatment, Including Systemic Therapy. Cancer Medicine. 2025;14(15). doi:10.1002/cam4.71129
BibTeX
@article{Sun2025,
author = {Sun, Steven and Cardona, Kenneth and Tseng, William W},
title = {Surgical Management of Retroperitoneal Liposarcoma: Opportunities for Multimodality Treatment, Including Systemic Therapy},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {15},
doi = {10.1002/cam4.71129}
}
EUVIMED